表紙
市場調査レポート

Angelini Group:製品パイプライン分析

Angelini Group - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 200925
出版日 ページ情報 英文 33 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Angelini Group:製品パイプライン分析 Angelini Group - Product Pipeline Review - 2015
出版日: 2015年12月23日 ページ情報: 英文 33 Pages
概要

当レポートでは、Angelini Groupにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Angelini Groupの基本情報

Angelini Groupの概要

  • 主要情報
  • 企業情報

Angelini Group:R&Dの概要

  • 主な治療範囲

Angelini Group:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Angelini Group:パイプライン製品の概況

  • 後期パイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Angelini Group:薬剤プロファイル

  • トラゾドン塩酸塩
  • prulifloxacin
  • bindarit
  • 中枢神経系および炎症性疾患のためのGSK-3 Betaを阻害する小分子
  • AF-3442
  • 感染症のためのジャイレースおよびTトポイソメラーゼIVを阻害する小分子
  • 癌、疼痛および消化器系疾患のためのMCPを阻害する小分子
  • 癌、疼痛および炎症のためのmPGES-1を阻害する小分子

Angelini Group:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Angelini Group:最近のパイプライン動向

Angelini Group:休止中のプロジェクト

Angelini Group:企業発表

Angelini Group:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07900CDB

Summary

Global Markets Direct's, 'Angelini Group - Product Pipeline Review - 2015', provides an overview of the Angelini Group's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Angelini Group's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Angelini Group including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Angelini Group's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Angelini Group's pipeline products

Reasons to buy

  • Evaluate Angelini Group's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Angelini Group in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Angelini Group's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Angelini Group and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Angelini Group
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Angelini Group and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Angelini Group Snapshot
    • Angelini Group Overview
    • Key Information
    • Key Facts
  • Angelini Group - Research and Development Overview
    • Key Therapeutic Areas
  • Angelini Group - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Angelini Group - Pipeline Products Glance
    • Angelini Group - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Angelini Group - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Angelini Group - Drug Profiles
    • trazodone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • prulifloxacin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit NAMPT for Pain and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug to Inhibit Prokineticin Receptor 1 for Pain and Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Beta Lactamase for Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit GSK-3 Beta for CNS Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Gyrase and Topoisomerase IV for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Angelini Group - Pipeline Analysis
    • Angelini Group - Pipeline Products by Target
    • Angelini Group - Pipeline Products by Route of Administration
    • Angelini Group - Pipeline Products by Molecule Type
    • Angelini Group - Pipeline Products by Mechanism of Action
  • Angelini Group - Recent Pipeline Updates
  • Angelini Group - Dormant Projects
  • Angelini Group - Company Statement
  • Angelini Group - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Angelini Group, Key Information
  • Angelini Group, Key Facts
  • Angelini Group - Pipeline by Indication, 2015
  • Angelini Group - Pipeline by Stage of Development, 2015
  • Angelini Group - Monotherapy Products in Pipeline, 2015
  • Angelini Group - Partnered Products in Pipeline, 2015
  • Angelini Group - Partnered Products/ Combination Treatment Modalities, 2015
  • Angelini Group - Pre-Registration, 2015
  • Angelini Group - Phase III, 2015
  • Angelini Group - Discovery, 2015
  • Angelini Group - Pipeline by Target, 2015
  • Angelini Group - Pipeline by Route of Administration, 2015
  • Angelini Group - Pipeline by Molecule Type, 2015
  • Angelini Group - Pipeline Products by Mechanism of Action, 2015
  • Angelini Group - Recent Pipeline Updates, 2015
  • Angelini Group - Dormant Developmental Projects,2015
  • Angelini Group, Subsidiaries

List of Figures

  • Angelini Group - Pipeline by Top 10 Indication, 2015
  • Angelini Group - Pipeline by Stage of Development, 2015
  • Angelini Group - Monotherapy Products in Pipeline, 2015
  • Angelini Group - Pipeline by Top 10 Target, 2015
  • Angelini Group - Pipeline by Top 10 Route of Administration, 2015
  • Angelini Group - Pipeline by Top 10 Molecule Type, 2015
  • Angelini Group - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top